All patients
Age < 65y (younger) Age > 65y cancer type (metastatic) cancer type (recurrent) ECOG 0 ECOG 1 Gender, female Gender, male P16 negative (HPV) P16 positive (HPV) smoker (Current) smoker (Former) smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
mHNSCC - 1st line (L1), immune chekpoint inhibitors vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.83 [0.70; 0.99]
KEYNOTE-048 (P vs C ; CPS > 1), 2019 0.78 [0.64; 0.96]
KEYNOTE-048 (P vs C ; CPS > 20), 2019 0.61 [0.45; 0.83]
KEYNOTE-048 (PC vs C ; all population), 2019 0.77 [0.63; 0.94]
KEYNOTE-048 (PC vs C ; CPS > 1), 2019 0.63 [0.51; 0.77]
KEYNOTE-048 (PC vs C ; CPS > 20), 2019 0.60 [0.44; 0.81]
0.72 [0.64 ; 0.80 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (P vs C ; CPS > 1), 2019, KEYNOTE-048 (P vs C ; CPS > 20), 2019, KEYNOTE-048 (PC vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; CPS > 1), 2019, KEYNOTE-048 (PC vs C ; CPS > 20), 2019 6 35% 2,631 moderate serious deaths (OS) (extension)detailed results KEYNOTE-048 (P vs C ; CPS > 1), 2019 0.74 [0.61; 0.90]
KEYNOTE-048 (P vs C ; CPS > 20), 2019 0.58 [0.44; 0.77]
KEYNOTE-048 (PC vs C ; all population), 2019 0.72 [0.60; 0.87]
0.70 [0.62 ; 0.79 ] KEYNOTE-048 (P vs C ; CPS > 1), 2019, KEYNOTE-048 (P vs C ; CPS > 20), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 3 3% 1,326 moderate not evaluable progression or deaths (PFS)detailed results KEYNOTE-048 (P vs C ; all population), 2019 1.34 [1.13; 1.59]
KEYNOTE-048 (P vs C ; CPS > 1), 2019 1.16 [0.96; 1.40]
KEYNOTE-048 (P vs C ; CPS > 20), 2019 0.99 [0.75; 1.30]
KEYNOTE-048 (PC vs C ; all population), 2019 0.92 [0.77; 1.10]
KEYNOTE-048 (PC vs C ; CPS > 1), 2019 0.82 [0.67; 1.00]
KEYNOTE-048 (PC vs C ; CPS > 20), 2019 0.73 [0.55; 0.97]
0.98 [0.82 ; 1.18 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (P vs C ; CPS > 1), 2019, KEYNOTE-048 (P vs C ; CPS > 20), 2019, KEYNOTE-048 (PC vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; CPS > 1), 2019, KEYNOTE-048 (PC vs C ; CPS > 20), 2019 6 78% 2,631 moderate not evaluable objective responses (ORR)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.36 [0.25; 0.53]
KEYNOTE-048 (P vs C ; CPS > 1), 2019 0.44 [0.29; 0.66]
KEYNOTE-048 (P vs C ; CPS > 20), 2019 0.11 [0.06; 0.20]
KEYNOTE-048 (PC vs C ; all population), 2019 0.97 [0.69; 1.37]
KEYNOTE-048 (PC vs C ; CPS > 1), 2019 1.03 [0.71; 1.49]
KEYNOTE-048 (PC vs C ; CPS > 20), 2019 1.21 [0.72; 2.05]
0.54 [0.29 ; 0.99 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (P vs C ; CPS > 1), 2019, KEYNOTE-048 (P vs C ; CPS > 20), 2019, KEYNOTE-048 (PC vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; CPS > 1), 2019, KEYNOTE-048 (PC vs C ; CPS > 20), 2019 6 92% 2,640 moderate not evaluable AE (any grade)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.31 [0.22; 0.44]
0.31 [0.22 ; 0.44 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable AE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 1.00 [0.69; 1.46]
1.00 [0.69 ; 1.46 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable AE leading to death (grade 5)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.84 [0.48; 1.48]
KEYNOTE-048 (PC vs C ; all population), 2019 1.21 [0.71; 2.07]
1.02 [0.69 ; 1.50 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable AE leading to treatment discontinuation (any grade)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.36 [0.23; 0.55]
KEYNOTE-048 (PC vs C ; all population), 2019 1.27 [0.89; 1.83]
0.68 [0.20 ; 2.35 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 95% 1,150 moderate not evaluable TRAE (any grade)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.05 [0.02; 0.09]
KEYNOTE-048 (PC vs C ; all population), 2019 0.71 [0.30; 1.72]
0.18 [0.01 ; 2.64 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 96% 1,150 moderate not evaluable TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.09 [0.06; 0.13]
KEYNOTE-048 (PC vs C ; all population), 2019 1.12 [0.78; 1.61]
0.32 [0.03 ; 3.76 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 99% 1,150 moderate not evaluable TRAE leading to death (grade 5)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.35 [0.09; 1.34]
KEYNOTE-048 (PC vs C ; all population), 2019 1.45 [0.57; 3.65]
0.78 [0.20 ; 3.08 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 66% 1,150 moderate not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 1.92 [0.06; 57.35]
KEYNOTE-048 (PC vs C ; all population), 2019 1.04 [0.02; 52.60]
1.47 [0.11 ; 19.25 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Anaemia TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.04 [0.01; 0.16]
KEYNOTE-048 (PC vs C ; all population), 2019 1.38 [0.89; 2.14]
0.25 [0.01 ; 8.25 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 95% 1,150 moderate not evaluable Asthenia TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.16 [0.02; 1.31]
KEYNOTE-048 (PC vs C ; all population), 2019 1.22 [0.40; 3.67]
0.54 [0.08 ; 3.85 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 65% 1,150 moderate not evaluable Blood and lymphatic system disorders TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.02 [0.01; 0.07]
KEYNOTE-048 (PC vs C ; all population), 2019 1.30 [0.92; 1.82]
0.18 [0.00 ; 9.02 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 98% 1,150 moderate not evaluable Blood creatinine increased TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.96 [0.02; 48.37]
KEYNOTE-048 (PC vs C ; all population), 2019 2.08 [0.07; 62.36]
1.49 [0.11 ; 19.48 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Colitis TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.96 [0.13; 6.84]
KEYNOTE-048 (PC vs C ; all population), 2019 1.04 [0.15; 7.44]
1.00 [0.25 ; 4.01 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Constipation TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.96 [0.02; 48.37]
KEYNOTE-048 (PC vs C ; all population), 2019 1.04 [0.02; 52.60]
1.00 [0.06 ; 15.99 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Decreased appetite TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.12 [0.01; 0.94]
KEYNOTE-048 (PC vs C ; all population), 2019 1.59 [0.64; 3.94]
0.51 [0.04 ; 6.46 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 80% 1,150 moderate not evaluable Diarrhoea TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.19 [0.02; 1.62]
KEYNOTE-048 (PC vs C ; all population), 2019 0.62 [0.15; 2.62]
0.43 [0.13 ; 1.42 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Endocrine disorders TRAE (grade 3-4) detailed results KEYNOTE-048 (P vs C ; all population), 2019 5.79 [0.29; 116.06]
KEYNOTE-048 (PC vs C ; all population), 2019 2.08 [0.07; 62.36]
3.70 [0.39 ; 35.06 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Fatigue TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.25 [0.07; 0.92]
KEYNOTE-048 (PC vs C ; all population), 2019 1.85 [0.87; 3.97]
0.74 [0.11 ; 5.15 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 85% 1,150 moderate not evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.07 [0.02; 0.23]
0.07 [0.02 ; 0.23 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable General disorders and administration site conditions TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.19 [0.08; 0.46]
KEYNOTE-048 (PC vs C ; all population), 2019 1.90 [1.15; 3.13]
0.62 [0.06 ; 5.93 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 95% 1,150 moderate not evaluable Hepatitis TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 3.85 [0.17; 85.65]
KEYNOTE-048 (PC vs C ; all population), 2019 2.08 [0.07; 62.36]
2.91 [0.29 ; 28.79 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 1.92 [0.06; 57.35]
KEYNOTE-048 (PC vs C ; all population), 2019 1.04 [0.02; 52.60]
1.47 [0.11 ; 19.25 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Hypophysitis TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 1.92 [0.06; 57.35]
KEYNOTE-048 (PC vs C ; all population), 2019 2.08 [0.07; 62.36]
2.00 [0.18 ; 22.10 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Hypothyroidism TRAE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 1.04 [0.02; 52.60]
1.04 [0.02 ; 52.60 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.31 [0.06; 1.57]
KEYNOTE-048 (PC vs C ; all population), 2019 0.34 [0.07; 1.71]
0.33 [0.11 ; 1.02 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Leucopenia TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.03 [0.00; 0.47]
KEYNOTE-048 (PC vs C ; all population), 2019 0.51 [0.21; 1.20]
0.17 [0.01 ; 2.60 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 73% 1,150 moderate not evaluable Metabolism and nutrition disorders TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.26 [0.14; 0.49]
KEYNOTE-048 (PC vs C ; all population), 2019 0.88 [0.55; 1.41]
0.48 [0.15 ; 1.62 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 89% 1,150 moderate not evaluable Mucosal inflammation TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.13 [0.03; 0.58]
KEYNOTE-048 (PC vs C ; all population), 2019 2.03 [1.04; 3.97]
0.56 [0.04 ; 8.18 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 91% 1,150 moderate not evaluable Myocarditis TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.96 [0.02; 48.37]
KEYNOTE-048 (PC vs C ; all population), 2019 2.08 [0.07; 62.36]
1.49 [0.11 ; 19.48 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Myositis TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.48 [0.02; 14.29]
KEYNOTE-048 (PC vs C ; all population), 2019 0.52 [0.02; 15.54]
0.50 [0.05 ; 5.51 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Nausea TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.03 [0.00; 0.47]
KEYNOTE-048 (PC vs C ; all population), 2019 0.97 [0.47; 2.01]
0.22 [0.01 ; 6.71 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 82% 1,150 moderate not evaluable Nephritis TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 3.85 [0.17; 85.65]
KEYNOTE-048 (PC vs C ; all population), 2019 1.04 [0.02; 52.60]
2.32 [0.20 ; 26.51 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Neutropenia TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.01 [0.00; 0.11]
KEYNOTE-048 (PC vs C ; all population), 2019 0.85 [0.56; 1.30]
0.09 [0.00 ; 10.60 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 91% 1,150 moderate not evaluable Pancreatitis TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.96 [0.02; 48.37]
KEYNOTE-048 (PC vs C ; all population), 2019 2.08 [0.07; 62.36]
1.49 [0.11 ; 19.48 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Pneumonitis TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 2.42 [0.46; 12.55]
KEYNOTE-048 (PC vs C ; all population), 2019 2.63 [0.51; 13.67]
2.52 [0.79 ; 8.08 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Rash TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.11 [0.02; 0.47]
KEYNOTE-048 (PC vs C ; all population), 2019 0.06 [0.01; 0.44]
0.09 [0.03 ; 0.28 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Severe skin reaction TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.29 [0.11; 0.73]
KEYNOTE-048 (PC vs C ; all population), 2019 0.10 [0.02; 0.45]
0.20 [0.08 ; 0.53 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 26% 1,150 moderate not evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed results KEYNOTE-048 (PC vs C ; all population), 2019 0.11 [0.03; 0.35]
0.11 [0.03 ; 0.35 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Stomatitis TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.05 [0.00; 0.80]
KEYNOTE-048 (PC vs C ; all population), 2019 2.40 [1.11; 5.16]
0.43 [0.01 ; 19.84 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 86% 1,150 moderate not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.04 [0.00; 0.27]
KEYNOTE-048 (PC vs C ; all population), 2019 1.04 [0.58; 1.89]
0.23 [0.01 ; 5.94 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 90% 1,150 moderate not evaluable Thyroiditis TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.96 [0.02; 48.37]
KEYNOTE-048 (PC vs C ; all population), 2019 1.04 [0.02; 52.60]
1.00 [0.06 ; 15.99 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Uveitis TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.96 [0.02; 48.37]
KEYNOTE-048 (PC vs C ; all population), 2019 1.04 [0.02; 52.60]
1.00 [0.06 ; 15.99 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Vomiting TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.09 [0.01; 1.73]
KEYNOTE-048 (PC vs C ; all population), 2019 1.47 [0.46; 4.68]
0.52 [0.04 ; 7.08 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 66% 1,150 moderate not evaluable Weight decreased TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.96 [0.06; 15.37]
KEYNOTE-048 (PC vs C ; all population), 2019 2.09 [0.19; 23.16]
1.49 [0.24 ; 9.20 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Abdominal pain AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.19 [0.02; 1.62]
KEYNOTE-048 (PC vs C ; all population), 2019 0.41 [0.08; 2.14]
0.31 [0.08 ; 1.14 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Acute kidney injury AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 1.93 [0.35; 10.60]
KEYNOTE-048 (PC vs C ; all population), 2019 2.63 [0.51; 13.67]
2.26 [0.69 ; 7.40 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Anaemia AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.24 [0.13; 0.44]
KEYNOTE-048 (PC vs C ; all population), 2019 1.65 [1.10; 2.49]
0.64 [0.10 ; 4.24 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 96% 1,150 moderate not evaluable Asthenia AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.31 [0.08; 1.16]
KEYNOTE-048 (PC vs C ; all population), 2019 1.04 [0.41; 2.66]
0.62 [0.19 ; 2.01 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 53% 1,150 moderate not evaluable Blood and lymphatic system disorders AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.10 [0.06; 0.18]
KEYNOTE-048 (PC vs C ; all population), 2019 1.39 [1.00; 1.94]
0.38 [0.03 ; 4.87 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 99% 1,150 moderate not evaluable Decreased appetite AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.28 [0.08; 1.03]
KEYNOTE-048 (PC vs C ; all population), 2019 1.37 [0.59; 3.18]
0.67 [0.14 ; 3.15 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 75% 1,150 moderate not evaluable Diarrhoea AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.23 [0.05; 1.11]
KEYNOTE-048 (PC vs C ; all population), 2019 1.04 [0.39; 2.81]
0.56 [0.13 ; 2.37 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 60% 1,150 moderate not evaluable Dyspnoea AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 2.26 [0.58; 8.83]
KEYNOTE-048 (PC vs C ; all population), 2019 1.39 [0.31; 6.28]
1.82 [0.66 ; 4.99 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Fatigue AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.60 [0.26; 1.42]
KEYNOTE-048 (PC vs C ; all population), 2019 1.52 [0.75; 3.08]
0.99 [0.40 ; 2.45 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 63% 1,150 moderate not evaluable Febrile neutropenia AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.03 [0.00; 0.47]
KEYNOTE-048 (PC vs C ; all population), 2019 1.61 [0.84; 3.11]
0.27 [0.01 ; 13.91 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 87% 1,150 moderate not evaluable Gastrointestinal disorders AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.33 [0.20; 0.56]
KEYNOTE-048 (PC vs C ; all population), 2019 1.38 [0.92; 2.06]
0.69 [0.17 ; 2.75 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 94% 1,150 moderate not evaluable General disorders and administration site conditions AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.42 [0.23; 0.75]
KEYNOTE-048 (PC vs C ; all population), 2019 1.71 [1.09; 2.67]
0.86 [0.22 ; 3.39 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 93% 1,150 moderate not evaluable Hypertension AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 7.74 [0.41; 147.13]
KEYNOTE-048 (PC vs C ; all population), 2019 17.10 [0.98; 299.27]
11.64 [1.49 ; 90.62 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Hypothyroidism AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.96 [0.02; 48.37]
0.96 [0.02 ; 48.37 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Increase AST AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.38 [0.07; 1.97]
KEYNOTE-048 (PC vs C ; all population), 2019 0.41 [0.08; 2.14]
0.39 [0.12 ; 1.27 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Leucopenia AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.03 [0.00; 0.47]
KEYNOTE-048 (PC vs C ; all population), 2019 0.57 [0.25; 1.31]
0.17 [0.01 ; 3.10 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 75% 1,150 moderate not evaluable Metabolism and nutrition disorders AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.51 [0.33; 0.77]
KEYNOTE-048 (PC vs C ; all population), 2019 1.11 [0.76; 1.63]
0.76 [0.35 ; 1.63 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 86% 1,150 moderate not evaluable Mucosal inflammation AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.25 [0.08; 0.75]
KEYNOTE-048 (PC vs C ; all population), 2019 1.97 [1.02; 3.78]
0.73 [0.10 ; 5.61 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 90% 1,150 moderate not evaluable Nausea AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.03 [0.00; 0.44]
KEYNOTE-048 (PC vs C ; all population), 2019 0.98 [0.48; 1.98]
0.21 [0.01 ; 6.94 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 83% 1,150 moderate not evaluable Nervous system disorders AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.40 [0.18; 0.85]
KEYNOTE-048 (PC vs C ; all population), 2019 0.90 [0.48; 1.67]
0.61 [0.28 ; 1.37 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 62% 1,150 moderate not evaluable Neutropenia AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.01 [0.00; 0.09]
KEYNOTE-048 (PC vs C ; all population), 2019 0.80 [0.53; 1.22]
0.11 [0.00 ; 6.60 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 94% 1,150 moderate not evaluable Pneumonitis AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.80 [0.41; 1.56]
KEYNOTE-048 (PC vs C ; all population), 2019 0.77 [0.38; 1.53]
0.78 [0.49 ; 1.27 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Rash AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.11 [0.02; 0.47]
KEYNOTE-048 (PC vs C ; all population), 2019 0.06 [0.01; 0.44]
0.09 [0.03 ; 0.28 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Renal and urinary disorders AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 1.15 [0.35; 3.81]
KEYNOTE-048 (PC vs C ; all population), 2019 1.90 [0.63; 5.75]
1.51 [0.67 ; 3.40 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Respiratory, thoracic and mediastinal disorders AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 2.17 [1.12; 4.18]
KEYNOTE-048 (PC vs C ; all population), 2019 2.56 [1.33; 4.91]
2.36 [1.48 ; 3.74 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Sepsis AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 2.91 [0.58; 14.53]
KEYNOTE-048 (PC vs C ; all population), 2019 2.10 [0.38; 11.53]
2.49 [0.77 ; 8.03 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Skin and subcutaneous tissue disorders AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 1.61 [0.58; 4.50]
KEYNOTE-048 (PC vs C ; all population), 2019 1.22 [0.40; 3.67]
1.42 [0.67 ; 3.00 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Stomatitis AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.05 [0.00; 0.80]
KEYNOTE-048 (PC vs C ; all population), 2019 2.52 [1.18; 5.39]
0.44 [0.01 ; 21.27 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 86% 1,150 moderate not evaluable Thrombocytopenia AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.03 [0.00; 0.25]
KEYNOTE-048 (PC vs C ; all population), 2019 1.00 [0.56; 1.78]
0.21 [0.01 ; 5.80 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 90% 1,150 moderate not evaluable Vascular disorders AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.76 [0.35; 1.64]
KEYNOTE-048 (PC vs C ; all population), 2019 1.57 [0.80; 3.09]
1.12 [0.55 ; 2.29 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 48% 1,150 moderate not evaluable Vomiting AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.12 [0.01; 0.94]
KEYNOTE-048 (PC vs C ; all population), 2019 1.31 [0.51; 3.37]
0.47 [0.05 ; 4.90 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 77% 1,150 moderate not evaluable Weight decreased AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 2.26 [0.58; 8.83]
KEYNOTE-048 (PC vs C ; all population), 2019 2.83 [0.74; 10.76]
2.53 [0.98 ; 6.58 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-06-02 10:09 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 277,102,109
- treatments: 204,504,850,329,558,579,549,868,502,741,556,812,813,367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,854,374,1073,953,672,1080,862,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,746,745,856,634,861,416,864,769,980,369,743
